Table 1.xls (9.5 kB)
Characteristics at enrolment.
dataset
posted on 2018-12-04, 18:24 authored by Cissy Kityo, Alexander J. Szubert, Abraham Siika, Robert Heyderman, Mutsa Bwakura-Dangarembizi, Abbas Lugemwa, Shalton Mwaringa, Anna Griffiths, Immaculate Nkanya, Sheila Kabahenda, Simon Wachira, Godfrey Musoro, Chatu Rajapakse, Timothy Etyang, James Abach, Moira J. Spyer, Priscilla Wavamunno, Linda Nyondo-Mipando, Ennie Chidziva, Kusum Nathoo, Nigel Klein, James Hakim, Diana M. Gibb, A. Sarah Walker, Sarah L. PettCharacteristics at enrolment.
History
Usage metrics
Keywords
225H12 weeks12- week raltegravir intensificationCD 4 counttranscriptase inhibitormutation K 219E24- week mortalityantiretroviral therapyNRTItriple-drug first-line therapy48 weekstriple-drug ARTNNRTImutations K 101ECIraltegravir-intensified ART18 June 201310 April 2015.aHRTrial registration International Standard Randomised Controlled Trials Number ISRCTN 43622374participantHIVTrial registration ClinicalTrials.gov NCT 01825031VL
